TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27482970
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg esmirtazapine
Study: 27482970
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg esmirtazapine
Study: 8677929
Drug: Salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalation
Study: 7599664
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of human menopausal gonadotropin (hMG) 150 IU
Study: 7599664
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of human menopausal gonadotropin (hMG) 150 IU
Study: 912132
Drug: Topical nitrogen
Normalized name: nitrogen Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitrogen mustard with and without tolerance induction
Study: 912132
Drug: PUVA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA in combination with Cyclophosphamide
Study: 30986736
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy with integrated elements of emotion‐focused therapy (CBT + EFT)
Study: 30986736
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy with treatment components based on self‐regulation theory (CBT + SR)
Study: 25929897
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation (28 capsules over 14 days, twice a day)
Study: 25929897
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (matching to probiotic preparation)
Study: 23587104
Drug: Self-administered structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered structured questionnaire assessing sexual health knowledge
Study: 17103172
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment group
Study: 15521667
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amphotericin B and endoscopic surgery, associated or not with Caldwell‐Luc surgery
Study: 2224121
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) 150 or 300 U/kg via intravenous (IV) bolus
Study: 2224121
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) 150 or 300 U/kg via subcutaneous (SC) injection
Study: 78095
Drug: Oestrogen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen treatment for first 4 years, followed by withdrawal
Study: 78095
Drug: Oestrogen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen treatment (first 4 years) vs. Placebo (full 8 years)
Study: 25575940
Drug: Fluticasone/formoterol (100/10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol (100/10, 250/10 or 500/20 μg b.i.d.)
Study: 25575940
Drug: Fluticasone (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100, 250 or 500 μg b.i.d.)
Study: 23070786
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group psychotherapy plus open methylphenidate treatment
Study: 11475711
Drug: Braun/Oral-B D7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun/Oral-B D7 powered toothbrush
Study: 11475711
Drug: Oral-B Advantage
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Advantage B35 manual toothbrush
Study: 27879044
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (PE) - dose-2 (640 mg phenolics/day)
Study: 24958282
Drug: DNA-damaging agents
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-damaging agents
Study: 15572639
Drug: Interviewer administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer administered mode (Control)
Study: 9055142
Drug: Eprosartan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (200 mg orally twice daily for 7 days)
Study: 9055142
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching oral doses for 7 days)
Study: 31216537
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (tolvaptan and reduced furosemide doses)
Study: 31216537
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (original furosemide dosage)
Study: 30216917
Drug: Methylphenidate, fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate, fixed dose
Study: 26935057
Drug: Low-dose CpG-B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CpG-B (CpG)
Study: 26935057
Drug: Low-dose CpG-B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CpG-B (CpG) + GM-CSF (GM)
Study: 20150394
Drug: Oral lipoic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipoic acid (1200 mg) - Formulation A
Study: 20150394
Drug: Oral lipoic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipoic acid (1200 mg) - Formulation B
Study: 20150394
Drug: Oral lipoic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipoic acid (1200 mg) - Formulation C
Study: 20150394
Drug: Subcutaneous lipoic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lipoic acid (20 mg/kg)
Study: 20150394
Drug: Subcutaneous lipoic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lipoic acid (50 mg/kg)
Study: 20150394
Drug: Subcutaneous lipoic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lipoic acid (100 mg/kg)
Study: 18333864
Drug: Maraviroc 100
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 100 mg b.i.d. + rifampicin 600 mg q.d.
Study: 18333864
Drug: Maraviroc 100
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 100 mg b.i.d. + efavirenz (EFV) 600 mg q.d.
Study: 18333864
Drug: Maraviroc 200
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 200 mg b.i.d. + rifampicin or EFV
Study: 18333864
Drug: Maraviroc 300
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300 mg b.i.d. + LPV/r (lopinavir 400 mg + ritonavir 100 mg)
Study: 18333864
Drug: Maraviroc 100
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 100 mg b.i.d. + SQV/r (saquinavir 1000 mg + ritonavir 100 mg)
Study: 23864314
Drug: Levodopa administration
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa administration
Study: 10412882
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg OD
Study: 540429
Drug: alpha‐receptor blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐receptor blockade (phentolamine 10 mg intravenously)
Study: 540429
Drug: combined alpha‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined alpha‐ and beta‐ receptor blockade (labetalol 100 mg intravenously)
Study: 31641967
Drug: PBMT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT + nonsurgical periodontal treatment (NSPT)
Study: 31641967
Drug: nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nonsurgical periodontal treatment (NSPT)
Study: 24002370
Drug: Atomoxetine 40
Normalized name: atomoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 40 mg
Study: 23692383
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg diclofenac HPβCD
Study: 23692383
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac HPβCD
Study: 23692383
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac HPβCD
Study: 19237898
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin (6 patients)
Study: 19237898
Drug: Bolus dosing
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dosing of piperacillin (7 patients)
Study: 16815689
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin
Study: 19237898
Drug: Bolus dosing
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dosing of piperacillin
Study: 17154733
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy
Study: 17541052
Drug: Dynamic supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic supportive treatment
Study: 26170105
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg
Study: 24195864
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg FeSO4
Study: 16259175
Drug: Low-intensity ultrasound
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity ultrasound therapy (20 minutes daily for six weeks)
Study: 7674504
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (antianginal therapy)
Study: 2206076
Drug: Oral terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline, 2.5 to 5 mg every 3 to 4 hours
Study: 2206076
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium oxide, 200 mg every 3 to 4 hours
Study: 6930206
Drug: Labetalol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (400 mg/day first month, average 585 mg/day second month)
Study: 6930206
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg/day first month, average 234 mg/day second month)
Study: 6930206
Drug: Labetalol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (higher dose)
Study: 6930206
Drug: Labetalol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol with diuretic
Study: 6930206
Drug: Propranolol (long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (long term therapy)
Study: 31365109
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment aimed at decreasing systolic BP by 10%-25% within the first 24 hours, achieving systolic BP <140 mm Hg and diastolic BP <90 mm Hg within 7 days, and maintaining this level during hospitalization.
Study: 31365109
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (discontinued all antihypertensive medications)
Study: 17143194
Drug: Aliskiren monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren monotherapy (75, 150 or 300 mg)
Study: 17143194
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aliskiren (300 mg) and HCTZ (25 mg)
Study: 17143194
Drug: HCTZ monotherapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCTZ monotherapy (6.25, 12.5 or 25 mg)
Study: 11841195
Drug: Flunisolide 500
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide 500 microg administered twice daily by nebulizer for 4 weeks
Study: 11841195
Drug: Budesonide 500
Normalized name: Budesonide 500 microgram/mL solution for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 500 microg administered twice daily by nebulizer for 4 weeks
Study: 8001599
Drug: New acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New acenocoumarol tablet formulation (12 mg single oral dose)
Study: 8001599
Drug: New acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New acenocoumarol tablet formulation
Study: 3892994
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (Heparin Leo 5000 I.U. subcutaneously twice daily)
Study: 29678962
Drug: Letter from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letter from GP outlining importance of asthma medication (delivered in late July)
Study: 1319601
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC
Study: 8712322
Drug: Metoclopramide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.25 mg.kg‐1
Study: 3888766
Drug: Intramuscular ceruletide
Normalized name: ceruletide diethylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceruletide
Study: 27435894
Drug: Adenosine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (4 to 512 μg)
Study: 19067728
Drug: Pegvisomant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (20 mg daily for 14 days)
Study: 14969833
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg/d administered preoperatively in HBV active replication group (15 recipients)
Study: 14969833
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg/d administered preoperatively in HBV inactive replication group (7 recipients)
Study: 9072566
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave lithotripsy (ESWL) monotherapy
Study: 8134206
Drug: Indomethacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1 mg/kg intravenously at 6 to 12 postnatal hours and every 24 hours for two more doses)
Study: 3310942
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg four times a day (short-term phase)
Study: 3310942
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg at bedtime (maintenance phase)
Study: 29288590
Drug: Ampcare Effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampcare Effective Swallowing Protocol (ESP), treatment 5 days/week for 4 weeks.
Study: 29288590
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (speech and language therapy dysphagia care).
Study: 22623396
Drug: D2 at
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 at 5 μg/d
Study: 22623396
Drug: D2 at
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 at 10 μg/d
Study: 22623396
Drug: D3 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 at 5 μg/d
Study: 22623396
Drug: D3 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 at 10 μg/d
Study: 12088961
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% with epinephrine 5 microg/mL
Study: 2196522
Drug: Standard methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methylphenidate (twice a day)
Study: 2196522
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate (SR-20 Ritalin)
Study: 2196522
Drug: Sustained-release dextroamphetamine
Normalized name: dextroamphetamine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release dextroamphetamine (Dexedrine Spansule)
Study: 19810365
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four medications
Study: 16970947
Drug: Moderate statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate statin treatment
Study: 11730209
Drug: PG synthesis
Normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG synthesis inhibitor (PGSI)
Study: 8229035
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (500 mg for five consecutive days)
Study: 8229035
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (500 mg for five consecutive days)
Study: 26206095
Drug: 750 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 μg vitamin D3
Study: 26206095
Drug: 1500 μg
Normalized name: flunixin
DrugBank: Flunixin (DB11518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 μg vitamin D3
Study: 23642949
Drug: Caralluma fimbriata
Normalized name: CARALLUMA FIMBRIATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caralluma fimbriata extract (500 mg capsules twice daily)
Study: 23642949
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg capsules twice daily)
Study: 17252909
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of pulsed low frequency magnetic field (PLFMF) with kinesitherapy
Study: 17252909
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of pulsed low frequency magnetic field (PLFMF) with kinesitherapy
Study: 9055905
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at daily doses of 0.1, 0.2, or 0.3 IU/kg (0.033, 0.067, or 0.1 mg/kg) s.c.
Study: 1390340
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily oral ondansetron
Study: 1390340
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily oral ondansetron
Study: 3493519
Drug: Beta-lactamase-susceptible agents
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactamase-susceptible agents
Study: 25958941
Drug: 0.7g CHO.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7g CHO.kg(‐1) supplement
Study: 25958941
Drug: 0.35g CHO.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35g CHO.kg(‐1) supplement
Study: 23663752
Drug: Apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 20 mg BID
Study: 23030767
Drug: Apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 20 mg QD
Study: 18293379
Drug: Intensive myeloablative
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHCR)
Study: 10717717
Drug: Methylprednisolone 240
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 240 mg daily for 3 days (group B)
Study: 10717717
Drug: Methylprednisolone 40
Normalized name: methylprednisolone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 40 mg daily for 3 days (group C)
Study: 1312317
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (18 Max-EPA capsules daily, 3.24 g eicosapentaenoic acid, 2.16 g docosahexaenoic acid)
Study: 2997764
Drug: Microcrystalline hydroxyapatite
Normalized name: Microcrystalline Hydroxyapatite Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline hydroxyapatite compound (MCHC)
Study: 28382392
Drug: Silicon nitride
Normalized name: Silicon nitride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon nitride implants
Study: 25456166
Drug: Daily 0.1-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 0.1-mg subcutaneous GnRHa until day of beta-HCG (n = 224)
Study: 25456166
Drug: Daily vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal progesterone suppositories (both groups)
Study: 25456166
Drug: Stopped GnRHa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopped GnRHa on day of HCG injection (n = 222)
Study: 23574148
Drug: Pre-emptive antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive antifungal treatment
Study: 23574148
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antifungal treatment)
Study: 20097587
Drug: Cetirizine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 0.4 mg/kg orally twice daily for 3 weeks
Study: 18007138
Drug: Oral hypoglycaemics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycaemics like metformin
Study: 11917051
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg added to ACEI regimen
Study: 30946525
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg extended-release tolterodine at bedtime
Study: 25960284
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (andrographolide sulfonate plus conventional therapy)